Novotech beefs up Asia-Pa­cif­ic CRO of­fer­ing with new buy­out as re­gion’s bio­phar­ma busi­ness booms

→ Asia-Pa­cif­ic CRO Novotech is ex­pand­ing, buy­ing out CRO Clin­i­cal Net­work Ser­vices as it builds up its ear­ly- to late-stage tri­al net­work in the re­gion.

CNS’ 140 staffers in Aus­tralia, New Zealand and the US will con­tin­ue to op­er­ate as an in­de­pen­dent unit, work­ing with the 400 staffers at Novotech in the Asia-Pa­cif­ic re­gion. No terms were pro­vid­ed.

CNS spe­cial­izes in ear­ly phase non-on­col­o­gy clin­i­cal tri­als across Aus­tralia and New Zealand, with Novotech spe­cial­iz­ing in “re­gion­al Asia-Pa­cif­ic and glob­al project de­liv­ery across all phas­es.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.